Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Am J Hematol. 2018 Jan 25;93(3):408–415. doi: 10.1002/ajh.25003

Figure 2.

Figure 2

Decline in FEV1 % predicted in the Sleep and Asthma Cohort (SAC) (mean ages 11 and 15 years), and extrapolated decline at later ages, as compared to the Cooperative Study of Sickle Cell Disease (CSSCD) (mean age 33 years) and Vanderbilt Cohort (mean age 32 years).